Analysts Clash on Moderna Stock Amid Vaccine Pipeline Optimism and Market Volatility

Moderna shares experienced trading volatility as analysts issued conflicting ratings, with some upgrading the stock due to robust vaccine development prospects while others cited broader market pressures and valuation concerns. The divergent views highlight ongoing uncertainty surrounding the biotech firm's near-term performance.